HemoGenyx Pharmaceuticals Plc (GB:HEMO)
LSE:HEMO
Want to see GB:HEMO full AI Analyst Report?
HEMO Stock Chart & Stats
568.00 p
-12.50 p(-3.23%)
At close: 4:00 PM EST
568.00 p
-12.50 p(-3.23%)
Day’s Range― - ―
52-Week Range124.00 p - 1,800.00 p
Previous CloseN/A
Volume114.00
Average Volume (3M)113.41K
Market Cap
£56.13M
Enterprise Value47.88M
Total Cash (Recent Filing)£1.59M
Total Debt (Recent Filing)£2.00M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding6,799,961
10 Day Avg. Volume30,447
30 Day Avg. Volume113,406
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Therapeutic NicheA clear, specialized focus on hematology and oncology (including stem cell transplantation) supports durable competitive advantage through deep domain expertise, clearer regulatory and clinical development pathways, and greater appeal to strategic partners or acquirers seeking targeted assets in blood-related cancers.
Debt Reduction TrendA multi-year decline in total debt is a durable improvement in financial structure. Lower debt reduces near-term financing pressure, improves flexibility for R&D funding or partnerships, and modestly reduces default and refinancing risk relative to prior years even if leverage remains elevated.
Reduced Cash Burn (2025 Vs 2024)A measurable reduction in operating cash outflows indicates better cost control or operational efficiency. If sustained, lower burn extends runway and decreases near-term dilution risk, giving management more time to progress programs or secure non-dilutive partnerships.
Bears Say
Pre-revenue With Widening LossesNo reported revenue combined with materially larger net losses drives persistent dependency on external funding. This structural state increases financing and execution risk, constrains reinvestment into development programs, and limits valuation upside until commercial revenues or material licensing occur.
Eroding Equity CushionA sharply reduced equity base weakens the company's ability to absorb ongoing losses and raises refinancing risk. With a smaller capital buffer, management faces tougher trade-offs between dilutive equity raises, debt financing, or cutting R&D—each of which can materially alter long-term strategic options.
Chronic Negative Cash GenerationSustained negative operating and free cash flow forces continual reliance on external capital and heightens dilution or covenant risk. This persistent cash shortfall is a durable constraint on program advancement and commercial readiness until the company generates internal cash or secures stable non-dilutive funding.
HemoGenyx Pharmaceuticals Plc News
HEMO FAQ
What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 124.00 p and its highest was 1800.00 p in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
HemoGenyx Pharmaceuticals Plc’s market cap is £56.13M.
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 24, 2026 which is in 101 days.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Apr 30, 2026. The company reported -0.787 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.787 p.
Is HemoGenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 6,799,961 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -0.787 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.735%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HemoGenyx Pharmaceuticals Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.23%
12-Months-Change
Fundamentals
Return on Equity
-2807.75%
Trailing 12-Months
Asset Growth
-0.85%
Trailing 12-Months
Company Description
HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
Technical Analysis
ImmuPharma
―
Open Orphan Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---